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Abstract
Background:  Microarrays revolutionized biological research by enabling gene expression
comparisons on a transcriptome-wide scale. Microarrays, however, do not estimate absolute
expression level accurately. At present, high throughput sequencing is emerging as an alternative
methodology for transcriptome studies. Although free of many limitations imposed by microarray
design, its potential to estimate absolute transcript levels is unknown.
Results: In this study, we evaluate relative accuracy of microarrays and transcriptome sequencing
(RNA-Seq) using third methodology: proteomics.  W e  f i n d  t h a t  R N A - Seq provides a better
estimate of absolute expression levels.
Conclusion: Our result shows that in terms of overall technical performance, RNA-Seq is the
technique of choice for studies that require accurate estimation of absolute transcript levels.
Background
The ability to measure messenger RNA (mRNA) expres-
sion levels of thousands of genes simultaneously gave an
enormous boost to biological research since the introduc-
tion of microarrays approximately 10 years ago. Microar-
rays, however, are designed for comparative studies and
provide only limited information about absolute gene
expression levels [1,2]. This limitation comes from differ-
ences in hybridization efficiency, as well as differences in
cross-hybridization background among millions of array
probes and is difficult to account for. This limitation,
however, is largely negligible for comparative, rather than
absolute, expression level analyses, explaining the enor-
mous utility of microarrays for a large spectrum of biolog-
ical studies. Still, accurate estimation of absolute
transcript levels is central to a number of applications.
Technically, it would allow combining mRNA expression
measurements produced by different platforms [3-5]. Bio-
logically, knowledge of absolute transcript levels within
cells and tissues would allow direct comparison to other
measurements from the same biological system, thus pro-
viding a basis for systematic evaluation and modelling of
regulatory processes [6-8]. Another important area of
application is splicing. In humans, as well as in other spe-
Published: 16 April 2009
BMC Genomics 2009, 10:161 doi:10.1186/1471-2164-10-161
Received: 13 November 2008
Accepted: 16 April 2009
This article is available from: http://www.biomedcentral.com/1471-2164/10/161
© 2009 Fu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genomics 2009, 10:161 http://www.biomedcentral.com/1471-2164/10/161
Page 2 of 9
(page number not for citation purposes)
cies, a great proportion of transcriptome complexity is
thought to arise through alternative splicing of exons
within a single genomic locus. In humans, for instance, at
least 47% of genes show evidence of alternative splicing
with nearly 3 isoforms per gene, on average [9]. Currently,
however, identification and quantification of individual
transcriptional isoforms is a major challenge. Accurate
estimation of absolute expression levels of individual
exons and exon junctions would greatly facilitate recon-
struction of all transcript isoforms simultaneously present
in the samples studied [10,11].
In the last few years, several novel high-throughput
sequencing technologies producing millions of sequences
per single sequencing run have emerged [12-15]. One
application of these technologies is transcriptome
sequencing, also known as RNA-Seq [13,16,17]. Such an
approach has several advantages over microarray technol-
ogy, including the ability to detect novel transcripts and
transcript isoforms, distinguish between closely related
paralogous sequences, and quantify expression in a "dig-
ital" rather than "analog" manner [13,16-18]. It remains
unclear, however, whether RNA-Seq can provide accurate
estimates of absolute transcript levels. Previous studies
have shown that sequencing reads density tends to vary
along the length of a transcript – an observation that indi-
cates RNA-Seq is not bias-free [13,16]. Biases, such as pref-
erential selection/exclusion of certain sequences, could
potentially take place during adapter ligation step, PCR
amplification, and/or sequencing itself. In fact, differ-
ences in ligation efficiency have been already demon-
strated in high-throughput sequencing experiments
[19,20]. Still, the effect these biases may have on estima-
tion of the absolute transcript levels is currently unknown.
Several recent studies have compared transcript expres-
sion levels measured in human and mouse samples using
both conventional microarrays and RNA-Seq [13,16]. In
all cases the expression levels showed good agreement
between the two technologies with correlations ranging
from 0.62 to 0.75. Still, correlation between the methods
is lower than the correlation between technical replicates
within each method (average, r = 0.96), leaving a large
proportion of differences between the methods unex-
plained. In this study, we use gene expression levels meas-
ured using a third technology – shotgun mass
spectroscopy – to assess the relative accuracy of the two
transcriptome quantification approaches with respect to
absolute transcript level measurements.
Results and Discussion
Here, we measure absolute gene expression levels in
human brain samples using three different methodolo-
gies: Affymetrix gene microarrays, high throughput
sequencing (Illumina, formerly Solexa), and mass spec-
trometry-based label-free proteomics. Among different
brain regions, we have chosen cerebellar cortex due to its
relative histological homogeneity, facilitating the dissec-
tion procedure and reducing biological variation due to
tissue heterogeneity [21]. All cerebellar tissues used in this
study came from individuals that suffered sudden death
for reasons unrelated to the brain, and mRNA quality was
high and comparable across all samples (see Additional
file 1: Table S1).
mRNA measurements by arrays and sequencing
We first determined whether we could reproduce the
agreement between mRNA expression estimates measured
by microarrays and by RNA-Seq reported in other studies.
For this purpose, we collected mRNA expression data in
two independent cerebellar samples, each containing
pooled mRNA from 5 adult human individuals, using
both methodologies (Methods). None of the individuals
was shared between the two pools. Using Affymetrix
Human Exon 1.0 ST Arrays, we found 8,717 and 6,444
genes with mRNA expression above the detection thresh-
old in the first and the second pooled samples, respec-
tively (Methods). Out of these genes, the vast majority
(6,424) was expressed in both samples. Further, gene
expression values in the two samples were highly corre-
lated (Person correlation, r = 0.95, p < 2.2e-16) (see Addi-
tional file 1: Figure S1). For RNA-Seq, we sequenced each
of the two pooled samples twice, resulting in a total of
5,067,363 sequence reads that could be mapped to the
human genome (Methods). In this dataset, 13,582 out of
21,541 annotated known protein-coding genes (Ensembl
release 49) were represented by at least two independent
sequences and 5,724 by at least 20 (Methods). Although
the total number of sequences differed among the four
sequencing experiments (see Additional file 1: Table S2),
gene expression levels estimated by sequence coverage
showed high positive correlation between both the bio-
logical and the technical replicates (see Additional file 1:
Figure S2). Thus, in agreement with previously published
studies, gene expression measurements show relatively lit-
tle variation within each method [13,16,17].
In further agreement with previous observations [13,16],
we find reasonably good positive correlation between
gene expression levels estimated by the two methods.
Namely, we observe Person correlation's r = 0.67 (p  <
2.2e-16) in a set of 8,441 genes with mRNA expression
detected above background in at least one of the two sam-
ples by both techniques (Figure 1A and 1C). The strength
of the correlation was similar when the two samples were
considered individually (r = 0.66 for both samples, Figure
1C and Additional file 1: Table S3). Further, the strength
of correlation did not depend much on the sequence cov-
erage and the array detection cutoff, or on the type of cor-
relation test used (see Additional file 1: Figure S3 and
Table S3).BMC Genomics 2009, 10:161 http://www.biomedcentral.com/1471-2164/10/161
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Next, to test whether biological variation among samples
would substantially reduce correlation strength, we com-
pared expression levels determined by RNA-Seq in two
pooled samples to the microarray data obtained from dif-
ferent individuals. For this purpose we used expression
measurements obtained using Affymetrix Exon Arrays in 5
individual adult human cerebellar samples, none of
which were included in the two pooled samples (see Addi-
tional file 1: Table S1). Using these data, we find that cor-
relations between microarray and RNA-Seq expression
measurements were reduced only slightly, both for the
average expression of the 5 individuals (Person correla-
tion r = 0.61, p < 2.2e-16) and for each of the individual
measurements (Figure 1B and 1D). In general, since indi-
vidual measurements from all 5 samples were highly cor-
related, combining any number of individuals did not
influence the result (Figure 1D and Additional file 1: Table
S3). Thus, individual variation among adult human cere-
bellar samples did not have much influence on the corre-
lation between microarray and RNA-Seq measurements.
Assessing mRNA measurements accuracy with proteomics 
data
Despite the observed agreement between microarray and
RNA-Seq expression measurements, the correlation is not
perfect leaving a relatively large proportion of total expres-
sion variation (from 48% in [13] to 57% in our data)
unexplained. In order to evaluate which methodology
provides better estimates of absolute mRNA expression
levels, we compared the two sets of mRNA expression
measurements to a third dataset: protein expression data
from adult human cerebellum. Protein data were col-
lected using 2D-LC MS/MS from four individual samples,
each with two experimental replicates (see Additional file
1: Table S1). In these data, we could identify 179,875 pep-
tides corresponding to 1,577 genes with peptide identifi-
cation FDR set to 0.5% (Methods). Out these genes, 1,037
represented by at least two peptides were included in the
following analysis.
Biologically, mRNA and protein expression levels cannot
be expected to correlate perfectly due to post-transcrip-
tional regulation. Nonetheless, positive correlation
between protein and mRNA expression levels has previ-
ously been shown in a variety of systems from bacteria to
mammals, with correlation coefficients ranging from 0.2
to 0.5 [6,22-27], thus indicating that mRNA and protein
expression levels are not fully independent. Further, since
technical and stochastic variation are extremely unlikely
to result in better correlation between mRNA and protein
expression measurements, we argue that the technology
resulting in better correlation must provide more accurate
measurements.
In agreement with previous results, we find only moderate
correlation between protein and mRNA expression levels
when using microarray measurements (Pearson correla-
tion, r = 0.24, p = 2.7e-8, N = 520). Using RNA-Seq expres-
sion measurements for the same set of genes, we find
substantially higher, albeit moderate, correlation (Pear-
son correlation, r = 0.36, p < 2.2e-16, N = 520). The differ-
ence between the two mRNA quantification
methodologies was significant (p < 0.05) and consistent
for both samples, as well as for their average, and did not
Correlation between mRNA expression levels measured by Affymetrix microarrays and RNA-Seq Figure 1
Correlation between mRNA expression levels measured by Affymetrix microarrays and RNA-Seq. mRNA 
expression levels measured by RNA-Seq in two pooled samples of 5 individuals and by microarrays in the same samples (A) or 
in 5 independent individual samples (B). Shown are expression levels of 8,441 and 4,758 genes, respectively, expressed above 
background on at least one of the microarrays in a given experiment and represented by at least two independent sequence 
reads in RNA-Seq (see Methods for details). (C and D) Person correlation coefficients (r) from comparisons between RNA-
Seq and microarray measurements based on each microarray separately and on average expression from all possible microar-
ray combinations for two pooled and 5 individual samples, respectively (see Additional file 1: Table S3 for details).
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depend on the sequence coverage depth, detection cutoff,
or type of the correlation test used (Figure 2C and Addi-
tional file 1: Table S4). Further, using microarray data
from five individual samples instead of the two pooled
samples gave similar results (Pearson correlation, r = 0.34,
p = 1.1e-9 and r = 0.42, p = 1.5e-14 for microarray and
RNA-Seq, respectively;N  = 306). Again, correlation
strength between protein and microarray measurements,
as well as that between protein and RNA-Seq, was consist-
ent among all samples and did not depend on the
sequence coverage depth, detection cutoff, or type of the
correlation test used (Figure 2F and Additional file 1:
Table S4). Notably, we consistently find better correlation
between mRNA and protein data using RNA-Seq measure-
ments, even though the same four individuals were used
for both proteomics and microarray measurements (see
Additional file 1: Table S1). Thus, individual or technical
variations do not explain the better agreement between
RNA-Seq and protein expression measurements among
samples used in this study. Finally, excluding all exons
shared by multiple isoforms and calculating transcript
expression using the highest level or the mean of all iso-
forms did not change the result (see Additional file 1: Fig-
ure S4). Taken together, our results indicate that,
following standard microarray and RNA-Seq methodol-
ogy, RNA-Seq provides a better estimate of observed pro-
tein levels than microarrays.
Correlation between protein and mRNA expression levels measured by Affymetrix arrays and RNA-Seq Figure 2
Correlation between protein and mRNA expression levels measured by Affymetrix arrays and RNA-Seq. Pro-
tein expression was measured in four individual samples with technical replicates. mRNA expression was measured by micro-
arrays and RNA-Seq in two pooled samples (A, B, and E), and by microarrays in 5 individual samples (D). Shown are expression 
intensities of 520 (A and B) and 306 (D and E) genes expressed above background on all microarrays in a given experiment and 
represented by at least twenty independent sequence reads in RNA-Seq. (Cand F) Person correlation coefficients (r) from 
comparisons between RNA-Seq and protein measurements (blue) and between microarray and protein measurements (red) 
for two pooled samples and 5 individual samples, respectively. For RNA-Seq data, the correlations were based on each 
sequencing experiment separately and on average expression from all possible experiment combinations. For microarrays, the 
correlations were based on expression values from each microarray separately and on average expression from all possible 
microarray combinations (see Additional file 1: Table S4 for details).
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We note that our method assesses the general accuracy of
these two techniques and is not developed as an approach
for verifying individual gene expression measurements in
a specific experiment. Instead, it demonstrates which tech-
nique, RNA-Seq or microarrays, provides more accurate
expression estimates as a methodology. Further, our
method estimates relative, rather than the absolute accu-
racies of the two techniques. Using RNA samples with
known concentrations spiked into the total RNA samples
would provide a more direct way to assess the techniques'
accuracy. Still, even though our results are limited to a par-
ticular array type and the sample preparation protocols
used, they should reflect the general relationship among
the three methodologies. In all three techniques, we esti-
mate gene expression levels using standard sample prepa-
ration and processing procedures. Further, in all three
techniques, an expression signal was calculated over the
entire gene length, rather than at a particular transcript
part. The Affymetrix microarrays used in this study,
Human Exon arrays, contain probes distributed over the
entire gene length [28]. In RNA-Seq and shotgun pro-
teomics, measurements are not restricted to predefined
probes and, therefore, could potentially detect sequences
and peptides corresponding to any location within a gene.
Further, for both microarrays and RNA-Seq, we used ran-
dom primers for the first-strand cDNA synthesis, thus
ensuring approximately uniform coverage along the tran-
scripts (Methods). Indeed, analysing the distribution of
expression measurements along genes, we find approxi-
mately uniform distribution for all three techniques (Fig-
ure 3). As this results in a greater total expression signal for
longer genes, we used gene expression measures inde-
pendent of gene length for all three techniques: average
sequence coverage for RNA-Seq, average expression level
of all detected array probes for microarrays, and average
copy number of all detected peptides for proteomics
(Methods). Thus, our results should reflect the general
relationship between gene expression measurements
obtained by the three techniques using comparable and
standard procedures.
Conclusion
In this study, we used protein expression measurements to
evaluate the accuracy of two mRNA quantification meth-
ods: microarrays and RNA-Seq. Our results show that
using standard microarray and RNA-Seq protocols, RNA-
Seq provides better estimates of absolute transcript levels.
This is particularly encouraging given that the original
methodological focus of high throughput sequencing is
genomic rather than transcriptomic studies. Thus, meth-
odological adjustments improving accuracy of transcript
level estimation by high throughput sequencing might be
possible. Our results indicate that RNA-Seq is already the
technique of choice for questions relying on accurate
absolute transcript level measurements.
Methods
Samples
Human tissue was obtained from the NICHD Brain and
Tissue Bank for Developmental Disorders at the Univer-
sity of Maryland, Baltimore, MD. The role of the NICHD
Brain and Tissue Bank is to distribute tissue, and therefore,
cannot endorse the studies performed or the interpreta-
tion of results. Informed consent for use of the human tis-
Distribution of expression signals within genes for the three methodologies Figure 3
Distribution of expression signals within genes for the three methodologies. The histograms show total signal den-
sity for 6424, 13582, and 1577 genes with detectable expression estimated by microarrays, RNA-Seq, or proteomics, respec-
tively. In order to account for length differences among genes, for each gene we normalized the distances between the middle 
positions of the detected expression measurements (array probes, sequence reads, or peptides) and the 5' end of the gene by 
the gene length.
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sues for research was obtained in writing from all donors
or the next of kin. All subjects were defined as normal con-
trols by forensic pathologists at the NICHD Brain and Tis-
sue Bank. No subjects with prolonged agonal state were
used. All samples were taken from the middle part of the
cerebellar cortex. No samples showed any detectable RNA
degradation, as measured using an Agilent Bioanalyzer
(Agilent Technologies, Palo Alto, USA) indicating good
tissue preservation. Details of all samples, including age,
sex, and RNA quality are given in Table S1.
RNA preparation and cDNA synthesis
Total RNA was extracted by Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer's instruc-
tions and treated for 30 min at 37°C with RNase free
DNase I (Ambion, Austin, TX). DNA-free total RNA was
purified with the RNeasy MinElute Kit according to the
manufacturer's instructions (Qiagen, Valencia, CA). Prior
to cDNA synthesis, 10 ug of total RNA was treated with
two rounds of RiboMinus kit (Invitrogen) to completely
remove the ribosomal RNA.
For the first strand of cDNA synthesis, 2 ug of rRNA-
Reduced total RNA was mixed with 500 ng of random
primer mix, incubated at 70°C for 5 minutes, and then
transferred to an ice bath. The first strand cDNA synthesis
was performed according to the standard protocol. Specif-
ically, in reaction mix containing 400 U of Superscript II
reverse transcriptase, 75 mM Tris Hcl, pH7.5, 100 mM
KCl, 5 mM MgCl2, 0.01 M DTT, and 20 mM dNTPs (Inv-
itrogen) in a total volume of 25 ul; this reaction mix was
incubated at 42°C for 60 minutes. The resulting first
strand cDNA was used to make second strand cDNA in a
reaction mix containing 20 mM dNTPs, 15 U of E. coli
DNA Polymerase I and 2 U of E. coli RNase H in a total
volume of 100 ul; this reaction mix was incubated at 16°C
for 2 hours. The resulting double stranded cDNA was
purified using the Qiaquick PCR purification kit (Qia-
gen). Samples were then fragmented with nebulization
technique to yield fragment sizes of 100–300 bps.
Library preparation for Illumina sequencing
The Illumina library was prepared according to the manu-
facturer's instructions [29] Specifically, the library was
purified with Qiaquick DNA purification kit (Qiagen).
The size-selected cDNA was blunt ended with End Repair
Enzyme in the presence of 2.5 mM dNTPs (NEB) and 10
mM ATP (Illumina, San Diego, CA). Adenine nucleotide
was added to the 3'ends of the blunt ended cDNA with
Klenow fragment (3' to 5' exominus) in the presence of 1
mM dATP (NEB) by incubating at 37°C for 30 minutes.
The end labeled double stranded cDNA was purified with
a Qiaquick DNA purification column (Qiagen). The dou-
ble stranded cDNA with A-nucleotides on its ends was
ligated with adapters (Illumina) using T4 DNA ligase at
room temperature for 15 minutes. The samples were then
purified with Qiaquick PCR purification kit (Qiagen).
Subsequently, the cDNA was amplified with two adapter
primers (Illumina) with initial denaturing step at 98°C
for 30 seconds, followed by 14 cycles at 98°C for 30 sec-
onds, 65°C for 30 seconds, 72°C for 30 seconds with a
final extension cycle at 72°C for 5 minutes. The PCR prod-
uct was purified with Qiaquick PCR purification kit. The
product size of 100–300 bp was gel extracted and used
directly for cluster generation and sequencing analysis
using Illumina's Solexa Sequencer according to the manu-
facturer's instructions. All sequences are available at http:/
/www.picb.ac.cn/Comparative/data.html.
Sequence mapping
To map the resulting 36-nucleotide long sequencing reads
to the human genes, we aligned all the reads against the
whole genome (hg18) and all the transcripts downloaded
from Ensembl database using the SOAP algorithm [30].
We allowed at most two mismatches in each alignment.
Reads with multiple "best hit" locations were discarded.
We calculated gene expression level as a median number
of reads mapped on its isoforms divided by the gene
length.
Microarray processing and analysis
mRNA samples for Affymetrix Human Exon 1.0 ST Arrays
were prepared following the standard GeneChip® Whole
Transcript (WT) Sense Target Labelling Assay (see manual,
P/N 701880) [28]. Prior to expression data analysis, we
masked all probes that did not match reference human
genomes perfectly (hg18) and did not map to a unique
location [31]. To determine whether the signal intensity
of a given probe was above the expected level of back-
ground noise, we compared the signal intensity for each
probe to a distribution of signal intensities of the antige-
nomic probes with the same GC content. Antigenomic
probes are specifically designed by Affymetrix to provide
an estimate of the non-specific background hybridization
[32]. The probe signal was classified as detected above
background if its intensity was larger than the 95% per-
centile of the background probes with the same GC con-
tent [33]. If more than 80% of probes and at least ten
probes per transcript were detected, the transcript signal
was classified as detected for each individual. To further
remove any possible systematic experimental differences
between the arrays, we performed a PM-GCBG correction
[32] and quantile normalization using R package "affy"
[34]. Prior to the normalization, all intensities were base-
two-logarithm transformed. The intensities of transcripts
were summarized by median polish method. We used the
Transcript Cluster Annotations file [28] to map the tran-
script clusters annotated by Affymetrix to Ensembl genes.
In cases where multiple transcript clusters mapped to the
same gene, we calculated gene expression as the median ofBMC Genomics 2009, 10:161 http://www.biomedcentral.com/1471-2164/10/161
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all corresponding transcript clusters. None of the tran-
script clusters overlapped. All original microarray data is
deposited in GEO database [GSE13744].
Protein sample preparation
Proteins were extracted from 100 mg of frozen cerebellar
tissue samples as described elsewhere [35,36] with small
modifications. Namely, each individual tissue sample was
minced, washed in ice-cold PBS and homogenized in ice-
cold lysis buffer (8 M urea, 4% CHAPS, 65 mM DTT, 40
mM Tris, cocktail protease inhibitor, 200 mg of tissue/1
ml) using an electric homogenizer. The resulting protein
solution was sonicated on ice for a total of 3 minutes and
then centrifugated at 25,000 g for 1 hour at 4°C to remove
DNA, RNA and cell debris. The protein supernatant was
precipitated using 5× volumes of precipitation solution
(ethanol:acetone:acetic acid at 50:50:0.1 volume ratio) at
4°C overnight, followed by centrifugation. The pellet was
dissolved in denaturing buffer (6 M guanidine hydrochlo-
ride, 100 mM Tris, cocktail protease inhibitor, pH 8.3)
and protein concentration determined by the Bradford
assay.
Protein digestion was performed as described elsewhere
[37]. Briefly, 600 μg proteins from each sample were
treated with DTT (100 μg/1 μl 1 M DTT), alkylated with
IAA (100 μg/2 μl 1 M IAA) and ultrafiltered with digestion
buffer (50 mM ammonium bicarbonate). The resulting
protein solution was incubated with Trypsin
(enzyme:protein at 1:40 mass ratio) at 37°C overnight,
followed by ultrafiltration and lyophilization. Lyophi-
lized protein samples were then dissolved in loading
buffer for the LC-MS/MS analysis.
2D LC-MS/MS analysis and peptide identification
Peptide fractionation and analysis was performed in a pH
continuous online gradient (pCOG) 2D LC-MS/MS sys-
tem as described elsewhere [38] with small modifications.
Briefly, the peptide solution was loaded on a SCX (Strong
Cation Exchange) column (320 μm × 100 mm Column
Technology Inc., CA, USA) and eluted resulting in 11 frac-
tions. Each of these fractions was then loaded on two RP
(Reversed Phase) alternative trap columns (320 mm, 620
mm, C18, 5 mm, Column Technology) using pH contin-
uous gradient buffer. The following RP gradient was used
to elute peptide fractions: 2 to 40% mobile phase (0.1%
formic acid (v/v) acetonitrile) in 120 min at 200 μL/min
flow rate before the split and 1.5 μL/min after the split.
Analysis was performed on the LTQ mass spectrometer
equipped with a metal needle electrospray interface mass
spectrometer (ThermoFinnigan, San Jose, CA, USA) in a
data-dependent collection model (each full scan followed
by ten MS/MS scans of most intense ions). All other
parameters used were set as described in [39].
The peptides were identified by searching against a com-
bined database of human peptides (IPI human v3.22) and
its reversed version using SEQUEST program in BioW-
orks™ 3.2 software suite. A mass tolerance of 3.0 Da and
one missed cleavage site of trypsin were allowed. Cysteine
carboxyamidomethlation was set as static modification
and no other modification was checked. All output results
were filtered and integrated to proteins by an in-house
software BuildSummary. At the false discovery rate (FDR)
less than 0.5%, all the matches passing a certain Xcorr and
delta CN were regarded as valid. Further, all the peptides
that could be assigned to multiple proteins were removed.
All the protein IDs were mapped to Ensembl gene IDs
using Biomart [40]. For each gene, we calculated protein
expression level as a median copy number of all peptides
mapped to any of the isoforms corresponding to this
gene.
Correlation analysis
To assess the correlation between different platforms, we
first set cutoffs to select subsets of genes with discernible
expression signals for each platform. Then, we calculated
both parametric (Pearson) and non-parametric (Spear-
man) correlation coefficients between the expression
measurements from each pair of platforms using overlap-
ping genes. In the comparison between protein and
mRNA expression data, the intersection of genes
expressed in all three datasets was used for both microar-
ray/protein and RNA-Seq/protein comparisons to ensure
comparability of the obtained correlation values.
For mRNA data, one stringent and one relaxed cutoff were
set. For microarrays, the stringent cutoff required expres-
sion values of a given gene to pass the detection cutoff (see
above) in all samples of the dataset: five individuals or
two pooled samples. The relaxed cutoff required expres-
sion values in at least one sample of the set to pass the
detection cutoff. For RNA sequencing data, the stringent
cutoff required at least twenty sequencing reads to map to
a given gene in all runs while the relaxed cutoff required
at least two reads. For protein expression data, we consid-
ered as expressed all 1,037 genes represented by at least
two independent peptides identified at FDR < 0.5% (see
above). Further, we repeated correlation analysis using
934 and 694 proteins expressed in the firsts and the sec-
ond set of technical replicates separately (see Additional
file 1: Figure S5).
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